Addendum
Migalastat (Fabry disease) – Addendum to Commission A23-88
Report documents
-
Addendum
Migalastat (Fabry disease) – Addendum to Commission A23-88
Dossier assessment
Indication:
Adults and adolescents aged 12 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation
Result of dossier assessment:
Unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2024-02-15 A G-BA decision was published.
Project details
- Project no.
- A24-10
- Commission
- Commission awarded on 16.01.2024 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://dx.doi.org/10.60584/A24-10_en
Connected Projects
-
Dossier assessment
Migalastat (Fabry disease) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed